

Identity:

Title: Professor
 Family Name(s): Mewton
 First Name(s): Nathan
 Age: 45 years

Photo:**Application for the following position in the HFA Board or Nominating Committee:**

Ordinary Board members

Place of work

If you work in multiple places, please provide the one where you spend the most time or that you consider to be your main place of practice.

Institute/organisation:	Hospices Civils de Lyon , Lyon University Claude Bernard
Department:	Cardiology, Heart Failure, Clinical Investigation Center
Address:	Hôpital Cardiologique Louis Pradel, GHE, 28 avenue Doyen Lépine,
Post code / Zip:	69500
Country:	F

General Curriculum Vitae (500 words max)

Please also include your H index and top 5 to 10 publications in the last 5 years

French –english origin

Current Position: Full time Professor in Cardiology, and Senior Physician in the Heart Failure Department of the Louis Pradel Cardiovasculaire Hospital and Université Claude Bernard Lyon 1, since 2018.

+15 years clinical experience in heart failure, general and intensive care cardiology

Team leader and manager of a clinical research department in cardiovascular disease for the Cardiology Department of the Hospices Civils de Lyon (University Hospital), France

Principal investigator or sub-investigator in +100 clinical research projects with + 200 publications referenced in PubMed, web of science **H-index 30**.

Rigorous, devoted, passionate, perseverant and strong institutional commitment.

Areas of expertise: heart failure, randomized trials, ischemia-reperfusion, microvascular obstruction, CMR, cardio-renal metabolism, advanced heart failure

Training :

2006 Medical Degree Specialization Degree in Cardiology – Université Claude Bernard – Lyon 1, France
 Board certification in Cardiology

2006-2008 University degree in Non-invasive cardiac imaging. Level 2 CMR degree Université Claude Bernard – Lyon 1, France

2006-2009 PhD degree of Université Claude Bernard Lyon 1, France Thesis deffense 22/12/2009 Ecole Doctorale Interdisciplinaire Sciences - Santé under the supervision of Pr. Pierre Croisille.

2010-2012- Post-Doctoral Research Fellowship – Johns Hopkins Hospital Cardiac Imaging Department– Chief of staff: Joao AC Lima Division of Cardiology Department of Medicine Baltimore, Maryland, USA

2011 Statistics Methods in Public Health Degree- Johns Hopkins Bloomberg School in Public Health

2018-2019 Post-graduate Course in Heart Failure from the ESC, University of Zurich.

Top 5 most recent publications H-index (web of science=30)

- 1) Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation. Obadia JF, Messika-Zeitoun D, Leurent G, (...) Vahanian A, **Mewton N**. N Engl J Med. 2018 Dec 13;379(24):2297-2306. doi:10.1056/NEJMoa1805374.
- 2) Prognostic impact of precipitated cardiac decompensation in symptomatic heart failure with reduced ejection fraction and severe secondary mitral regurgitation. **Mewton N**, et al. Am Heart J. 2023 Nov;265:83-91. doi: 10.1016/j.ahj.2023.05.016
- 3) Sequencing and titrating approach of therapy in heart failure with reduced ejection fraction following the 2021 European Society of Cardiology guidelines: an international cardiology survey. Fauvel C, Bonnet G, Mullens W, Giraldo CIS, (...), **Mewton N**. Eur J Heart Fail. 2023 Feb;25(2):213-222. doi: 10.1002/ejhf.2743.
- 4) Effect of Colchicine on Myocardial Injury in Acute Myocardial Infarction. **Mewton N**, et al. Circulation. 2021 Sep 14;144(11):859-869. doi: 10.1161/CIRCULATIONAHA.121.056177.
- 5) Colchicine in acute myocardial infarction: cardiovascular events at 1-year follow up. Bouleti C, Viscogliosi S, Bresson D, Leboube S, (...) **Mewton N**. Open Heart. 2024 Jan 17;11(1):e002474. doi: 10.1136/openhrt-2023-002474.

Describe previous experience within the HFA, ESC and/or your National Cardiac/ HF Society

150 words maximum

I have been an ESC professional member since 2014, and an HFA silver to gold member since 2018.

In 2022 I have integrated the HFA working groups of Communication with Amina Rakiseva as leader and was also involved in the Scientific Committee on Cardiac Devices led by Offer Amir.

I have been actively involved in the social media team of the ESC as ambassador in the 2023 HFA and ESC meetings in Prague and Amsterdam.

Previously, I was invited to several talks and submitted several abstracts to the HFA and I have participated actively to the HF3 registry (EORP).

Through the Zurich PCHF (2018-2019), we have built an international network of alumniees and led 2 international surveys on HF practice.

I have been involved in the French Heart Failure group from the French Society of Cardiology since 2015, and I am the current Secretary of the group (GICC), since 2024.

Why are you motivated to join the HFA Board or Nominating Committee?

150 words maximum

As a heart failure specialist, a physician in the care of general and advanced HF patients, a clinical researcher participating in many randomized trials and a professor in Cardiology focused on heart failure, I am strongly motivated to take an active part in the Heart Failure Association activities.

Participating in the Zurich PCHF, I have developed a European network of friends and a real interest in the HFA and the promotion of heart failure within the ESC. **I feel truly European.** As an ESC professional member, HFA gold member, and active part of 2 working groups of the HFA, I am interested to step up and promote a strong community, where the horizons of Europe are represented and involved into collective actions (research, education, emulation, health policies).

I am applying because I feel that the HFA has become the core of the ESC and has a major role within this community to promote better cardiovascular care with a personalized approach to each patient. I would like to impact this community in a significant and positive way and being part of the HFA board is in resonance with this goal.

How will you combine your HFA position with your daily clinical/research workload?

80 words maximum

If I am elected to the HFA board, this will become one of my personal responsibility and priority. Participating to each board meeting in person will be set up ahead in my agenda, and will make time for abstract review and congress planning and all other activities entrusted to me by the HFA.